[Neoadjuvant therapeutic principles guided by response prediction and evaluation]
1Chirurgische Klinik und Poliklinik, Technische Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 München.
Kongressband. Deutsche Gesellschaft Fur Chirurgie. Kongress
|April 23, 2003
Summary
Identifying nonresponders to neoadjuvant therapy early is crucial for improved survival. Tumor metabolism changes detected by FDG-PET show high accuracy in predicting treatment response, guiding future clinical study designs.
Area of Science:
- Oncology
- Medical Imaging
- Pharmacology
Background:
- Neoadjuvant therapy improves survival only in patients with documented clinical and pathohistological response.
- Identifying nonresponders early is essential for optimizing treatment strategies and improving patient outcomes.
- Predictors for treatment response and early identification of nonresponders are critically needed.
Purpose of the Study:
- To evaluate the potential of early metabolic changes detected by FDG-PET as a predictor of neoadjuvant therapy response.
- To assess the role of biochemical investigations of target enzymes in predicting treatment outcomes.
- To inform the design of future clinical studies based on early response prediction.
Main Methods:
- Preliminary biochemical investigations of target enzymes (e.g., TS, ERCC1) for cytostatics.
- Analysis of early changes in tumor metabolism using Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET).
Main Results:
- Biochemical investigations of target enzymes show promising preliminary data.
- Early metabolic changes in FDG-PET can identify nonresponders with a high negative predictive value (88-95%).
Conclusions:
- FDG-PET offers a reliable method for the early identification of nonresponders to neoadjuvant therapy.
- These findings necessitate adjustments in the design and execution of future clinical trials.
- Integrating early response prediction into clinical practice is vital for personalized cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...